{"anticipatedPostingDate":"2010-05","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Response Evaluation Criteria in Solid Tumors (RECIST) criteria: Complete Response (CR)-Disappearance of all target lesions (TL); Partial Response (PR)-\\< or = 30% decrease in the sum of the longest diameter (LD) of TL, reference baseline sum LD; Stable Disease (SD)-Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, reference the smallest sum LD since the treatment started; Progressive Disease (PD)- \\< or = 20% increase in the sum of the LD of TL, reference the smallest sum LD recorded since treatment started or appearance of \\< or = 1 new lesion.","groups":[{"description":"This group includes patients with recurrent ovarian, fallopian tube or primary peritoneal cancer who received at least one dose of chemotherapy (cyclophosphamide 60 mg/m\\^2 and fludarabine 25 mg/m\\^2 for 2 doses, and aldesleukin 10 million units for 6 doses), infusion of natural killer cells (1.5-8.0 \\* 10\\^7 kg) and no total body irradiation.","id":"OG000","title":"No Total Body Irradiation"},{"description":"This group includes patients with recurrent ovarian, fallopian tube or primary peritoneal cancer who received at least one dose of chemotherapy (cyclophosphamide 60 mg/m\\^2 and fludarabine 25 mg/m\\^2 for 2 doses, and aldesleukin 10 million units for 6 doses), infusion of natural killer cells (1.5-8.0 \\* 10\\^7 kg) and total body irradiation (200 Gy on Day 1 preceding natural killer cell infusion).","id":"OG001","title":"Total Body Irradiation"}],"paramType":"NUMBER","populationDescription":"Includes 12 patients that completed treatment per protocol criteria.","reportingStatus":"POSTED","timeFrame":"1 Month After Natural Killer Cell Infusion (Day 30)","title":"Number of Patients Per Disease Response","type":"SECONDARY","unitOfMeasure":"Patients"}